What Should Specialty Pharmacists Know About the ReDOS Clinical Trial?

Article
Conference|Gastrointestinal Cancers Symposium

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.

Related Videos
Young depressed woman talking to lady psychologist during session, mental health - Image credit: motortion | stock.adobe.com
Related Content
Image credit: Iliya Mitskavets | stock.adobe.com

Considerations When Treating Migraines in Gender Diverse Patients Receiving Gender-Affirming Hormone Therapy

April 23rd 2024
Article
Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

January 25th 2024
Podcast
Microglia are immune cells in the brain | Image Credit: Artur - stock.adobe.com

Study: Frexalimab Shows Sustained Reduction of Disease Activity for Multiple Sclerosis

April 23rd 2024
Article
Pharmacy Focus: Policy Edition - PBM Audits

Pharmacy Focus: Policy Edition - PBM Audits

January 24th 2024
Podcast
3d rendered illustration of lung cancer 3D illustration | Image Credit: appledesign - stock.adobe.com

Samsung Bioepis Initiates Phase 3 Clinical Trial for Proposed Pembrolizumab Biosimilar

April 22nd 2024
Article
nerve cells, Neurologic Disease, tumors, brain surgery | Image Credit: ralwel - stock.adobe.com

Ocrelizumab Demonstrates Near-Complete Suppression of Relapses for Multiple Sclerosis

April 22nd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.